Deep Mind, a British AI expert who carried out the AI Go "Alpha Go" program, launched a prototype of a medical device that can diagnose severe eye diseases within 30 seconds. This is the first time that Deep Mind has released a real commercial product, not a software program, according to the Financial Times (FT) on Monday. Deep mind is Google's parent company, an alphabetical subsidiary. In 2016, he announced his name for the 9th stadium and Alpha's Conflict That Baduk.
Deep Mind recently showed the diagnosis of real-time offthalm diseases by analyzing patients' retina with a medical device and analyzing its own algorithm. It took less than 30 seconds to scan the retina scan image and introduce the ophthalmologic diseases and crisis rate according to the distribution in four stages, the FT said.
This product can be used for detailed diagnosis of eye diseases such as glaucoma, diabetic retinopathy, macular degeneration. In terms of accuracy, we pride ourselves on the same level as the world's best ophthalmologists, and experts say it is much faster than them. It was developed in conjunction with Moore Fields Hospital, a famous UK ophthalmology hospital for the last three years, and was published in Nature magazine in August last year.
"This device helps patients not to wait to see a specialist and miss out on the untreated after-effects," says Perthkian Ophthalmologist at Moore Fields Hospital. As the number of patients suffering from ophthalmological diseases increases as the population ages, the number of retina scans increases, but there is a lack of experts to read.
"The first thing to do is get an ophthalmology clinic where the situation will change quickly by AI," Ki-Nun said. Initial tests showed around 50 outbreaks of ophthalmologic disease, and the power ratio was 94%. "We have over 20 years experience in this field," said Alan Caine Salin, a senior clinical scientist at Deep Mind.
The device is unlikely to threaten the lives of local eye surgeons immediately, says Deepmind. Deep thoughts said, "This medical device assists ophthalmologists and gives doctors another weapon." Local clinicians can use the device to find complex eye diseases and use it as a tool to decide whether or not to send patients to specialist hospitals.
Clinical trials and accreditation processes remain. Algorithm-based medical devices were approved by the Food and Drug Administration of the United States (FDA) and are already in use.
[email protected] park Hyun-young reporter